Sold as Prefest. Every FDA application for this active ingredient: 1 branded and 1 generic.
As of Nov 15, 2026, FDA lists 2 applications for Estradiol; Norgestimate (sold as Prefest), first approved Oct 22, 1999, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Prefest | Part D | $0K | -100% | 0 |
| Effects of VX-407 on the Pharmacokinetics of Combined Oral ContraceptivesAutosomal Dominant Polycystic Kidney Disease (ADPKD) · Vertex Pharmaceuticals Incorporated | Phase 1 | Recruiting | Aug 28, 2026 |
| Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or ObesityOverweight, Obesity · Amgen | Phase 1 | Active, not recruiting | Apr 13, 2026 |
| International Active Surveillance Study: Safety of Estrogen Estetrol (E4) Contraceptive Study (INAS-SEECS)Contraception · Center for Epidemiology and Health Research, Germany | — | Recruiting | Dec 29, 2023 |
| Oct 22, 1999 | PrefestNDA 21040 · New combination | Teva Womens | 13 | Discontinued |
| Apr 29, 2005 | Estradiol And NorgestimateANDA 76812 | Barr | 4 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
